Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.

Author information

1
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands. lisanne@lisannekrens.nl.
2
ZGT Pharmacy, Hospital Group Twente, Boerhaavelaan 63, 7555 BB, Hengelo, The Netherlands. lisanne@lisannekrens.nl.
3
Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
4
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.

Abstract

PURPOSE:

Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min.

METHODS:

Pharmacokinetic parameters, including dose-normalized area under the curve, clearance and elimination half-life (T 1/2) after the 11th and 12th infusions were estimated using trapezoidal non-compartmental methods. Data were compared to previous reported pharmacokinetic data from studies in patients with normal renal function.

RESULTS:

The results show that the pharmacokinetic data in this patient with kidney failure are comparable to those in patients with adequate renal function. Moreover the treatment was well tolerated in this patient.

CONCLUSION:

This study suggests that panitumumab can be safely used in cancer patients with renal impairment without dose adjustment.

KEYWORDS:

Colorectal cancer; Panitumumab; Pharmacokinetics; Renal insufficiency

PMID:
29170802
PMCID:
PMC5754392
DOI:
10.1007/s00280-017-3479-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center